The	O
Therapeutic	B:C1527144
Effect	I:C1527144
of	O
Berberine	B:C0005117
in	O
the	O
Treatment	B:C0087111
of	O
Nonalcoholic	B:C0400966
Fatty	I:C0400966
Liver	I:C0400966
Disease	I:C0400966
:	O
A	O
Meta-Analysis	B:C0920317
Aim	O
.	O

To	O
assess	O
the	O
efficacy	O
of	O
berberine	B:C0005117
in	O
the	O
treatment	B:C0087111
of	O
nonalcoholic	B:C0400966
fatty	I:C0400966
liver	I:C0400966
disease	I:C0400966
through	O
meta-analysis	B:C0920317
.	O

We	O
searched	O
Embase	B:C0282574
,	O
Pubmed	B:C1138432
,	O
Cochrane	B:C0282574
Library	I:C0282574
,	O
and	O
so	O
forth	O
,	O
until	O
March	O
2016	O
for	O
randomized	B:C0282440
controlled	I:C0282440
trials	I:C0282440
using	O
berberine	B:C0005117
to	O
treat	O
NAFLD	B:C0400966
.	O

Six	O
randomized	B:C0282440
controlled	I:C0282440
trials	I:C0282440
involving	O
501	O
patients	O
were	O
included	O
in	O
this	O
study	B:C2603343
.	O

The	O
results	O
showed	O
that	O
the	O
efficacy	O
of	O
reducing	O
TC	B:C0543421
,	O
LDL	B:C0023823
,	O
ALT	B:C0001899
,	O
2hPG	O
,	O
and	O
HbA1c	B:C0019018
in	O
NAFLD	B:C0400966
patients	O
of	O
the	O
berberine	B:C0005117
group	B:C1257890
were	O
significantly	O
higher	O
than	O
that	O
of	O
control	O
group	O
.	O

The	O
subgroup	B:C1257890
analyses	O
on	O
TG	B:C0041004
,	O
AST	B:C0004002
,	O
and	O
FBG	B:C0428568
indicated	O
that	O
treatment	B:C0087111
combined	O
with	O
berberine	B:C0005117
decreased	O
TG	B:C0428475
level	I:C0428475
in	O
NAFLD	B:C0400966
patients	O
significantly	O
.	O

Compared	O
with	O
other	O
drugs	B:C0013227
,	O
berberine	B:C0005117
alone	O
decreased	B:C0428475
TG	I:C0428475
level	I:C0428475
in	O
NAFLD	B:C0400966
patients	O
significantly	O
.	O

We	O
also	O
conducted	O
a	O
descriptive	B:C0936012
analysis	I:C0936012
on	O
insulin	B:C0021655
resistance	I:C0021655
and	O
radiography	B:C0043299
results	O
that	O
berberine	B:C0005117
can	O
improve	O
NAFLD	B:C0400966
patients	O
'	O
insulin	B:C0021655
resistance	I:C0021655
and	O
fatty	B:C0015695
liver	I:C0015695
.	O

According	O
to	O
analysis	O
result	O
,	O
berberine	B:C0005117
has	O
positive	O
efficacy	O
on	O
blood	O
lipids	O
,	O
blood	B:C0005802
glucose	I:C0005802
,	O
liver	B:C0232741
function	I:C0232741
,	O
insulin	B:C0021655
resistance	I:C0021655
,	O
and	O
fatty	B:C0015695
liver	I:C0015695
condition	I:C0015695
of	O
NAFLD	B:C0400966
patients	O
.	O

However	O
,	O
due	O
to	O
the	O
limitation	O
of	O
number	O
and	O
quality	O
of	O
trials	O
included	O
,	O
more	O
clinical	O
randomized	B:C0282440
controlled	I:C0282440
trials	I:C0282440
with	O
high	O
quality	O
are	O
needed	O
for	O
further	O
verification	O
of	O
the	O
efficacy	O
of	O
berberine	B:C0005117
on	O
NAFLD	B:C0400966
patients	O
.	O

